.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Argus Health
Merck
Citi
Covington
Julphar
Mallinckrodt
Boehringer Ingelheim
Dow
Chubb

Generated: July 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205003

« Back to Dashboard
NDA 205003 describes PRESTALIA, which is a drug marketed by Symplmed Pharms Llc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the PRESTALIA profile page.

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

Summary for NDA: 205003

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 205003

Suppliers and Packaging for NDA: 205003

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL 205003 NDA Symplmed Pharmaceuticals, LLC 61894-010 61894-010-02 90 TABLET in 1 BOTTLE, PLASTIC (61894-010-02)
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL 205003 NDA Symplmed Pharmaceuticals, LLC 61894-011 61894-011-02 90 TABLET in 1 BOTTLE, PLASTIC (61894-011-02)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE;3.5MG
Approval Date:Jan 21, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 21, 2018
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Apr 15, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF HYPERTENSION
Patent:► SubscribePatent Expiration:Oct 5, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF HYPERTENSION


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Julphar
UBS
Chinese Patent Office
Cantor Fitzgerald
Argus Health
Express Scripts
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot